TY - JOUR
T1 - Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer
AU - Tarantini, Luigi
AU - Cioffi, Giovanni
AU - Gori, Stefania
AU - Tuccia, Fausto
AU - Boccardi, Lidia
AU - Bovelli, Daniella
AU - Lestuzzi, Chiara
AU - Maurea, Nicola
AU - Oliva, Stefano
AU - Russo, Giulia
AU - Faggiano, Pompilio
PY - 2012/2
Y1 - 2012/2
N2 - Background: Adjuvant trastuzumab therapy improves survival of human epidermal growth factor receptor 2 (HER2)-positive women with early breast cancer (EBC). A careful monitoring of cardiac function is needed due to potential trastuzumab cardiotoxicity (Tcardiotox). To date, the incidence, timing, and phenotype of patients with Tcardiotox in clinical practice are not well known. Methods and Results: A total of 499 consecutive HER2-positive women (mean age 55 ± 11 years) with EBC treated with trastuzumab between January 2008 and June 2009 at 10 Italian institutions were followed for 1 year. We evaluated incidence, time of occurrence, and clinical features associated with Tcardiotox. Left ventricular ejection fraction (LVEF) was evaluated by echocardiography at baseline and at 3, 6, 9, and 12 months during trastuzumab therapy. Tcardiotox was recognized in 133 patients (27%): 102 (20%) showed asymptomatic reduction in LVEF of >10% but ≤20% (grade 1 Tcardiotox); 15 (3%) had asymptomatic decline of LVEF of >20% or
AB - Background: Adjuvant trastuzumab therapy improves survival of human epidermal growth factor receptor 2 (HER2)-positive women with early breast cancer (EBC). A careful monitoring of cardiac function is needed due to potential trastuzumab cardiotoxicity (Tcardiotox). To date, the incidence, timing, and phenotype of patients with Tcardiotox in clinical practice are not well known. Methods and Results: A total of 499 consecutive HER2-positive women (mean age 55 ± 11 years) with EBC treated with trastuzumab between January 2008 and June 2009 at 10 Italian institutions were followed for 1 year. We evaluated incidence, time of occurrence, and clinical features associated with Tcardiotox. Left ventricular ejection fraction (LVEF) was evaluated by echocardiography at baseline and at 3, 6, 9, and 12 months during trastuzumab therapy. Tcardiotox was recognized in 133 patients (27%): 102 (20%) showed asymptomatic reduction in LVEF of >10% but ≤20% (grade 1 Tcardiotox); 15 (3%) had asymptomatic decline of LVEF of >20% or
KW - adjuvant chemotherapy
KW - Breast cancer
KW - cardiotoxicity
KW - heart failure
KW - trastuzumab
UR - http://www.scopus.com/inward/record.url?scp=84856439776&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856439776&partnerID=8YFLogxK
U2 - 10.1016/j.cardfail.2011.10.015
DO - 10.1016/j.cardfail.2011.10.015
M3 - Article
C2 - 22300778
AN - SCOPUS:84856439776
VL - 18
SP - 113
EP - 119
JO - Journal of Cardiac Failure
JF - Journal of Cardiac Failure
SN - 1071-9164
IS - 2
ER -